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Abstract 
Background 
Intestinal inflammation is partly driven by enteroglial-derived S100B protein. The 
antiprotozoal drug pentamidine directly blocks S100B activity. We aimed to investigate the 
effect of pentamidine on intestinal inflammation using an animal model of dextran sodium 
sulphate (DSS)-induced acute colitis. 
Methods 
Mice were divided into: control group, colitis group (4% DSS for four days) and two 
pentamidine-treated colitis groups (0.8 mg/kg and 4 mg/kg). Anti-inflammatory effect of 
pentamidine was assessed in colonic tissue by evaluating the disease activity index and the 
severity of histological changes. Colonic tissue were also used to evaluate cyclooxigenase-2, 
inducible nitric oxide synthase, S100B, glial fibrillary acidic protein, phosphorylated-p38 
MAPkinase, p50, p65 protein expression, malondyaldheyde production, mieloperoxidase 
activity, and macrophage infiltration. Nitric oxide, prostaglandin E2, interleukin-1 beta, tumor 
necrosis factor alpha, and S100B levels were detected in plasma samples. Parallel 
measurements were performed in vitro on dissected mucosa and longitudinal muscle 
myenteric plexus (LMMP) preparations after challenge with LPS + DSS or exogenous S100B 
protein in the presence or absence of pentamidine. 
Results 
Pentamidine treatment significantly ameliorated the severity of acute colitis in mice, as 
showed by macroscopic evaluation and histological/biochemical assays in colonic tissues and 
in plasma. Pentamidine effect on inflammatory mediators was almost completely abrogated 
in dissected mucosa but not in LMMP. 
Conclusions 
Pentamidine exerts a marked anti-inflammatory effect in a mice model of acute colitis, likely 
targeting S100B activity. Pentamidine might be an innovative molecule to broaden 
pharmacological tools against colitis. 
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Background 
Although the etiology of ulcerative colitis (UC) remains incompletely understood, severe and 
persistent mucosal infiltration of macrophages and neutrophils in the large intestine 
represents a prominent feature [1]. Immune cells release cytokines, interleukins and 
proinflammatory signaling molecules [2-4]. In addition to the well-known involvement of 
macrophages and neutrophils, other cell types have been recently reported to substantially 
contribute to the onset and progression of the disease. Enteric glial cells (EGC) play a 
fundamental role in the maintenance of gut homeostasis since they have trophic and 
protective functions toward enteric neurons and are fully implicated in the modulation of 
neuronal activities [5]. Moreover, EGC have been repeatedly reported to trigger and support 
intestinal inflammation [6] and to function as a first line of defense against pathogens [7]. 
EGC may proliferate and be activated in response to injury and inflammation undergoing 
reactive gliosis (enterogliosis), a condition in which they release neurotrophins, growth 
factors and proinflammatory cytokines cross-talking with other infiltrating immune cells [8]. 
Alterations in the homeostasis of the enteric nervous system are induced by reactive 
enterogliosis and characterized by the massive overexpression and secretion of specific 
astroglial-derived signaling molecules such as S100B protein [9,10]. 
S100B is a diffusible, Ca++/Zn++-p53 binding protein playing a pivotal role during intestinal 
inflammation, since it orchestrates proinflammatory signals [11,12]. Aberrant expression and 
release of S100B correlate with the inflammatory status of the gut. S100B accumulates at the 
RAGE (receptor for advanced glycation end products) site only in micromolar concentrations 
[11,13-15] and such interaction leads to mitogen-activated protein kinase (MAPK) 
phosphorylation and consequent nuclear factor-kappaB (NF-κB) activation, which, in turn, 
promote the transcription of different cytokines and inducible nitric oxide synthase (iNOS) 
protein [14]. Molecular targeting of S100B protein during intestinal inflammation might 
therefore represent an innovative approach to treat UC. 
Pentamidine isethionate, discovered to have antiprotozoal activity in 1938, and approved in 
the United States for the treatment of Pneumocystis carinii pneumonia and other protozoal 
diseases [16], appears to be an intriguing candidate. In addition to its antiprotozoal activity, 
pentamidine has been reported to inhibit S100B activity because of its ability to block the 
interaction at the Ca++/p53 site of the protein [17]. 
Based on this background, the present study was aimed at evaluating the beneficial effect of a 
daily administration of pentamidine in an acute model of UC induced by dextran sulphate 
sodium (DSS) administration in drinking water in CD-1 mice. DSS-induced colitis is highly 
reproducible and is a well-known in vivo model of experimental colitis in rodents that 
reproduces many features of UC [18]. We tested the effect of pentamidine on (i) intensity of 
the symptoms (diarrhea, blood in the feces, animal weight loss) through a disease activity 
index (DAI) scale [19]; (ii) release of cytokines and proinflammatory signaling molecules 
present in mice plasma; (iii) postmortem evaluation of macroscopic shortening of large 
intestine and spleen weight; (iv) global colonic inflammation by the evaluation of 
biochemical and histological changes of the tissue. 
Methods 
Animals and experimental design 
Six-weeks-old male CD-1 mice (25 to 35 g; Harlan Laboratories, Udine, Italy) were used for 
the experiments. Animals were randomly divided into five groups (n = 10 each): noncolitic 
control group; colitic group; colitic group receiving daily pentamidine 0.8 mg/kg; colitic 
group receiving daily pentamidine 4 mg/kg; noncolitic group receiving daily pentamidine 4 
mg/kg (as drug internal control). Colitis was induced by administrating DSS (4% w/v, MW 
36,000 to 50,000) in drinking water for six consecutive days (starting from day 1), as 
described in Figure 1A. Pentamidine was given intraperitoneally starting at day 2 through day 
6. At day 7, animals were sacrificed and tissues were removed to perform macroscopic, 
histochemical and biochemical analyses as described below. 
Figure 1 (A) Dextran sulphate sodium (DSS)-exposed (4%) mice were treated daily with 
0.8 mg/kg or 4 mg/kg pentamidine given intraperitoneally. Effect of pentamidine on (B) 
DAI score, (C) colonic length and (D) spleen weight in DSS-treated mice. Results are 
expressed as mean ± SEM of n = 5 experiments. ***P <0.001 vs. vehicle (saline); °P <0.05; 
°°P <0.01 and °°°P <0.001 vs. DSS. DAI, disease activity index. 
Disease activity index (DAI) 
The DAI scale is based on the evaluation of different parameters characterizing experimental 
colitis induction and progression. Body weight, presence of gross blood in the feces and stool 
consistency were recorded daily (from day 0 to 7) by an observer blinded to the treatment. 
According to the criteria proposed by Cooper et al. [19], the DAI was determined by scoring 
changes in: weight loss (0 = none; 1 = 1 to 5%; 2 = 5 to 10%; 3 = 10 to 20%; 4 = >20%); 
stool consistency (0 = normal; 2 = loose; 4 = diarrhea) and rectal bleeding (0 = normal; 2 = 
occult bleeding; 4 = gross bleeding). At the end of the experiment, mice were sacrificed and 
colons and spleens were isolated to measure the length and weight of colon and spleen, 
respectively. 
Preparation of cytosolic extracts and western blot analysis 
Removed colonic tissues were processed for western blot analysis. Briefly, after 
homogenization in ice-cold hypotonic lysis buffer, protein concentration was determined 
using Bio-Rad protein assay kit (Bio-Rad, Milan, Italy). Analysis of cyclooxigenase (COX)-
2, iNOS, TNF-α, S100B, glial fibrillary acidic protein (GFAP), phosphorylated-p38 (p-p38) 
MAPK, p50, p65 and β-actin protein expression was performed on total protein fractions of 
homogenates. Equivalent amounts (50 µg) of each homogenate underwent electrophoresis 
through a polyacrilamide minigel. Proteins were then transferred onto nitrocellulose 
membrane that were saturated by incubation with 10% nonfat dry milk in 1× PBS overnight 
at 4°C and then incubated with either mouse anti-S100B (1:200 v/v, Neo-Marker, Milan, 
Italy), mouse anti-iNOS (1:2000 v/v, BD Biosciences, Milan, Italy), rabbit anti-COX-2 
(1:250 v/v, BD Biosciences), GFAP (1:5000 v/v, Abcam, Cambridge, UK), mouse anti-p50, 
mouse anti-p65 (1:1000 v/v, Santa Cruz Biotechnology, Santa Cruz, CA, USA), or mouse 
anti-β-actin (1:1,000 v/v, Santa Cruz Biotechnology) for 2 h at room temperature (RT). 
Membranes were then incubated with anti-mouse or anti-rabbit immunoglobulins coupled to 
peroxidase (1:2000 v/v, Dako, Milan, Italy). Immune complexes were revealed by using 
enhanced chemiluminescence detection reagents (Amersham Biosciences, Milan, Italy) and 
exposed to Kodak X-Omat film (Eastman Kodak Co., Rochester, NY, USA OK). Protein 
bands were then scanned and densitometrically analyzed with a GS-700 imaging 
densitometer. 
Preparation of blood samples 
Before being sacrificed, mice were deeply anesthetized and the blood was taken by cardiac 
puncture and collected in 5% EDTA vials. To determine nitric oxide (NO), prostaglandin E2 
(PGE2), IL-1β, TNF-α, and S100B levels, plasma was isolated from the blood, immediately 
frozen, and stored at −80°C until the assays. 
Plasma NO quantification 
NO was measured as nitrite (NO2-) accumulation in plasma. A spectrophotometer assay based 
on the Griess reaction was used [20]. Briefly, Griess reagent (1% sulphanilamide, 0.1% 
naphthylethylenediamine in H3PO4) was added to an equal volume of plasma and the 
absorbance was measured at 550 nm. NO2- concentration (nM) was thus determined using a 
standard curve of NaNO2. 
Plasma PGE2, TNF-α, S100B, and IL-1β quantification 
Quantitative determination of PGE2, IL-1β, TNF-α, and S100B was carried out performing 
enzyme linked-immunosorbent assay (ELISA) on plasma samples (PGE2, TNF-α, IL-1β kits 
were from Invitrogen, Milan, Italy; S100B kit was from BioVendor, Heidelberg, Germany) 
according to the manufacturer’s kit instructions. 
Macrophage infiltration in the mucosa 
Samples for immunohistochemical assessment were isolated from distal colon and fixed in 
4% paraformaldehyde, embedded in paraffin, sectioned in 15 µm slices and processed for 
immunohistochemistry. Slices were pretreated for 20 min using heat-mediated antigen 
retrieval with a sodium citrate buffer, incubated with MAC387 [21] (1 µg/ml, Abcam) for 15 
min at RT, and detected using horseradish peroxidase (HRP)-conjugated compact polymer 
system. DAB was used as the chromogen. Slices were then counterstained with hematoxylin, 
mounted with Eukitt and analyzed with a microscope (Nikon Eclipse 80i by Nikon 
Instruments Europe, Amstelveen, Netherlands). Images were captured by a high-resolution 
digital camera (Nikon Digital Sight DS-U1). 
p53 Immunofluorescence 
Colon slices derived from both control and treated mice were blocked in 10% bovine serum 
albumin 0.1% Triton-PBS solution for 90 min at RT and subsequently stained for 1 h at RT 
with anti-p53 antibody (1:1250, Santa Cruz Biotechnology) and anti-MAC387 (1:200, 
Abcam). Sections were then incubated for 1 h at RT in the dark with the proper secondary 
antibody: fluorescein isothiocyanate-conjugated anti-rabbit (1:100, Abcam) or Texas Red-
conjugated anti-mouse (1:64, Abcam), respectively. Nuclei were stained with Hoechst 
(1:5000, Sigma-Aldrich, Milan, Italy). Slides were thus analyzed with a microscope (Nikon 
Eclipse 80i by Nikon Instruments Europe), and images were captured at 10X and 20X 
magnification by a high-resolution digital camera (Nikon Digital Sight DS-U1). 
Myeloperoxidase (MPO) assay 
MPO, a marker of polymorphonuclear leukocyte accumulation and general inflammation 
occurring in colonic tissue, was determined as previously described [22]. After removal, 
colonic tissue was rinsed with cold saline, opened and deprived from the mucosa using a 
glass slide. The resulting layer was then homogenized in a solution containing 0.5% 
hexadecyltrimethylammonium bromide dissolved in 10 mM potassium phosphate buffer (pH 
7.0) and centrifuged for 30 min at 20000 × g at 37°C. An aliquot of the supernatant was 
mixed with a solution of tetramethylbenzidine (1.6 mM) and 0.1 mM H2O2. The absorbance 
was then spectrophotometrically measured at 650 nm. MPO activity was determined as the 
amount of enzyme degrading 1 mmol of peroxide per minute at 37°C and was expressed in 
milliunits per 100 mg of wet tissue weight. 
Lipid peroxidation assay 
Malonyl dialdehyde (MDA) was measured by the thiobarbituric acid colorimetric assay [23] 
in colonic tissue. Briefly, 1 mL 10% (w/v) trichloroacetic acid was added to 450 µl of tissue 
lysate. After centrifugation, 1.3 mL 0.5% (w/v) thiobarbituric acid was added and the mixture 
was heated at 80°C for 20 min. After cooling, MDA formation was recorded (absorbance 530 
nm and absorbance 550 nm) in a Perkin Elmer (Waltham, MA, USA) spectrofluorimeter and 
the results were presented as ng MDA/mL. 
Mucosa and LMMP preparations 
In order to further evaluate the putative site and the mechanism of action of pentamidine, 
additional experiments were set up as follows. Colonic segments (approximately 1.5 cm long) 
were isolated from another set of CD-1 mice not previously used for any in vivo treatment. 
Mice were euthanized by injection of pentobarbital sodium (100 mg/kg) and distal colon was 
removed and cut longitudinally to expose the mucosa. Under sterile conditions, the tissues 
were placed in Dulbecco’s modified Eagle's medium (supplemented with 5% fetal bovine 
serum, 2 mM glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, all from Invitrogen), 
pinned flat and the mucosa was carefully peeled off to obtain the longitudinal muscle-
myenteric plexus (LMMP) layer [24]. Depending upon the experimental plan, both mucosa 
and LMMP were stimulated for 24 h with exogenous lipopolysaccharide (LPS) (10 µg/ml) + 
DSS (1% w/v) or exogenous S100B (5 µM, Sigma-Aldrich, Milan, Italy), with or without the 
addition of pentamidine (0.5 to 5 µM) administered to the tissue 10 min prior to LPS + DSS 
or S100B stimulus. 
Statistical analysis 
Results were expressed as mean ± SEM of experiments. Statistical analysis was performed 
using parametric one-way analysis of variance (ANOVA) and multiple comparisons were 
performed by Bonferroni's post hoc test. P values <0.05 were considered significant. 
Results 
Pentamidine ameliorates DAI score, preserves colonic length and reduces 
splenomegaly induced by DSS 
Starting from day 4 after DSS administration, DAI score was significantly increased in DSS 
groups. As expected, DSS caused a consistent increase in bloody diarrhea together with loss 
of body weight, as compared to control group (Figure 1B). DSS also caused a significant 
shortening of colon and a marked increase of spleen weight (Figure 1C and D). Pentamidine 
treatment inhibited the rise in DAI score in a dose-dependent way, suggesting an overall 
improvement of intestinal symptoms associated with colitis after DSS administration; such 
effect was accompanied by a reduction of bloody stools, diarrhea frequency, and a rescue of 
body weight (Figure 1B). Moreover, pentamidine was able to preserve colonic length and to 
prevent splenomegaly in DSS-treated mice (Figure 1C and D). 
Pentamidine inhibits intestinal inflammation induced by DSS 
In Figure 2 it is shown that the administration of DSS caused a marked increase of iNOS, 
COX-2, S100B and GFAP protein expression compared to control mice. Pentamidine 
treatment resulted in a dose-dependent attenuation of iNOS, COX-2 and GFAP but not of 
S100B protein overexpression (Figure 2A and B). As expected, Griess reaction and ELISA 
demonstrated that the administration of DSS caused a significant increase in plasma NO2- 
level, PGE2, IL-1β, TNF-α and S100B, compared to control mice (Figure 3). Also in this case 
and according to western blot results, pentamidine treatment caused a marked and dose-
dependent attenuation of all the inflammatory mediators in plasma, except for S100B release 
that remained unaffected after pentamidine treatment. 
Figure 2 (A) Western blot analysis showing the effect of pentamidine on iNOS, COX-2, 
GFAP and S100B protein expression in colonic tissue of DSS-treated mice; (B) relative 
quantification of immunoreactive bands (arbitrary units). Results are expressed as mean 
± SEM of n = 5 experiments performed in triplicate. ***P <0.001 vs. vehicle (saline); °°P 
<0.01 and °°°P <0.001 vs. DSS. COX2, cyclooxigenase-2; DSS, dextran sodium sulphate; 
GFAP, glial fibrillary acidic protein; iNOS, inducible nitric oxide synthase. 
Figure 3 Effect of pentamidine on the release of inflammatory mediators (NO2-, PGE2, 
IL-1β, TNF-α) and S100B in plasma of DSS-treated mice. Results are expressed as mean ± 
SEM of n = 5 experiments performed in triplicate. ***P <0.001 vs. vehicle (saline); °°P 
<0.01 and °°°P <0.001 vs. DSS. DSS, dextran sodium sulphate; IL-1β, interleukin-1 beta; 
NO, nitric oxide; PGE2, prostaglandin E2; TNF-α, tumor necrosis factor alpha. 
Pentamidine inhibits S100B-induced lipid peroxidation, p38 MAPK 
phosphorylation, and NF-κB activation induced by DSS 
Further characterizing the inhibitory effect of pentamidine, we found that in DSS-treated 
mice the increase in S100B expression was accompanied by a significant increase in lipid 
peroxidation and phosphorylation of p38 MAPK (Figure 4A and B). These effects were 
related to both p50 and p65 protein overexpression and indicated the activation of NF-κB 
(Figure 4B). In our experimental conditions, pentamidine significantly and dose-dependently 
inhibited MDA accumulation, p38 MAPK phosphorylation and, consequently, NF-κB 
activation. 
Figure 4 (A) Effect of pentamidine on MDA production in colonic tissue of DSS-treated 
mice; (B) immunoblots showing the effect of pentamidine on p-p38 MAPK, p50 and p65 
protein expression in colonic tissue of DSS-treated mice; (C) relative quantification of 
immunoreactive bands. Results are expressed as mean ± SEM of n = 5 experiments 
performed in triplicate. ***P <0.001 vs. vehicle (saline); °P <0.05, °°P <0.01 and °°°P 
<0.001 vs. DSS. DSS, dextran sodium sulphate; MDA, malondialdehyde; p-p38 MAPK, 
phosphorylated-p38 MAPkinase. 
Pentamidine reduces DSS-induced macrophage infiltration and MPO activity 
Colonic mucosa was extensively infiltrated by macrophages in DSS-treated mice compared 
to control mice (Figure 5A and B). Such increase was accompanied as well by neutrophil 
infiltration, as showed by the increased MPO activity (Figure 5C). Pentamidine treatment 
caused a significant and dose-dependent reduction in macrophage infiltration together with 
significant and dose-dependent inhibition of MPO activity, indicating that pentamidine is able 
to control neutrophil infiltration in colonic tissues (Figure 5A and B). 
Figure 5 (A) Effect of pentamidine on macrophage infiltration in colonic tissue of DSS-
treated mice: pentamidine dose-dependently reduced macrophages infiltration. Arrows 
indicate MAC387 immunopositive macrophages infiltrating colon criptae; (B) Quantification 
of MAC387 immunopositive macrophages in colon criptae. Data are expressed as mean ± 
SEM of n = 3 experiments; (C) effect of pentamidine on MPO level in colonic tissue of DSS-
treated mice. Results are expressed as mean ± SEM of n = 6 experiments. ***P <0.001 vs. 
vehicle (saline); °°P <0.01 and °°°P <0.001 vs. DSS. Original magnification 100X. DSS, 
dextran sodium sulphate; MPO, mieloperoxidase. 
Pentamidine induces p53 expression in infiltrating macrophages 
Macrophage infiltration in the colonic tissues from DSS-treated mice was confirmed by 
immunofluorence (Figure 6A). Pentamidine treatment significantly and dose-dependently 
reduced macrophage infiltration (Figure 6A). Very interestingly, such decrease was 
accompanied by the reverse trend in p53 expression. In fact, p53 resulted negative in the 
colon from control and DSS-treated mice, while a strong immunopositivity was found in 
colonic tissues from pentamidine-treated mice (Figure 6). Moreover, p53 expression was 
found in macrophages, as revealed from the co-expression with MAC387, a specific 
macrophage marker [21] (Figure 6). 
Figure 6 (A) Immunofluorescence analysis of colonic tissues showing the effect of 
pentamidine on macrophage infiltration induced by DSS: pentamidine dose-
dependently inhibited macrophage infiltration (MAC387, red) and increased p53 
expression (green) in colon criptae. Arrows indicate MAC387/p53 co-expression; (B) 
relative quantification (MAC387+/p53 + area/total area percentage) of macrophage 
infiltration and p53 expression in DSS-treated mice. Data are expressed as mean ± SEM of n 
= 3 experiments. Original magnification 200X. DSS, dextran sodium sulphate. 
S100B-dependent effect of pentamidine 
An internal check for the expression of S100B protein was performed in both mucosal and 
LMMP preparations confirming that the protein was expressed exclusively in the LMMP 
layer (Figure 7A). Preparations were separately challenged with DSS (1%) plus LPS (1 
µg/ml) or S100B (5 µM) in the presence or absence of pentamidine (0.5 to 5 µM). 
Stimulation with LPS + DSS caused a marked proinflammatory response in the mucosa as 
well as in LMMP preparations, as demonstrated by the increase in nitrites level, PGE2 and 
TNF-α level compared to respective nonstimulated preparations (Figure 7B and C). Very 
interestingly, pentamidine had no significant beneficial effect on the mucosa while it 
significantly and concentration-dependently reduced the release of nitrites, PGE2 and TNF-α 
in LMMP preparations (Figure 7C). Exogenous application of S100B to the mucosa caused a 
significant increase in nitrites, PGE2, and TNF-α level (Figure 7B). As confirmation for the 
S100B-dependent effect, pretreatment with pentamidine significantly and concentration-
dependently reduced S100B-induced inflammation in the mucosa (Figure 7C). 
Figure 7 (A) Western blot analysis showing S100B protein expression in mucosa (M) 
and in LMMP preparations. Effect of pentamidine on inflammatory mediators (NO2-, 
PGE2, IL-1β, TNF-α) in mucosa (B) and in LMMP (C) in the presence of different 
proinflammatory stimuli (LPS + DSS or exogenous S100B depending upon the experiments). 
Results are expressed as mean ± SEM of n = 5 experiments. ***P <0.001 vs. vehicle (saline); 
°P <0.05, °°P <0.01 and °°°P <0.001 vs. proinflammatory stimulus DSS, dextran sodium 
sulphate; IL-1β, interleukin-1 beta; LMMP, longitudinal-muscle myenteric plexus; LPS, 
lipopolysaccharide; NO, nitric oxide; TNF-α, tumor necrosis factor alpha. 
Discussion 
The results of the present study indicate that pentamidine is capable to profoundly and 
beneficially impact on an animal model of acute colitis. The model we used has been 
demonstrated to resemble UC features [18]. Prevailing therapies for UC include chronic 
administration of glucocorticosteroids and mesalamine [25,26]. Steroids are effective in the 
short-term treatment of acute flares of UC but they are not suitable as a maintenance therapy 
due to a variety of systemic adverse reactions [27]. Sulfasalazine and its derivative 5-
aminosalicylic acid are effective only in mild-to-moderate acute phase of the disease and in 
preventing relapse. Biological drugs such as monoclonal anti-TNF-α antibody (infliximab 
and adalimumab) have been recently introduced in the therapy of relapsing inflammatory 
bowel disease with encouraging results in the maintenance of remission [28]. However, the 
long-term safety of these drugs, the possibility to induce severe side effects [29-31] together 
with the high costs of the therapy for the patients warrant novel and alternative 
pharmacological approaches. 
We demonstrated that pentamidine efficiently and dose-dependently improved colitis. It 
caused attenuation of the DAI together with preservation of colonic length and reduction of 
splenomegaly induced by DSS-colitis. Besides inducing such macroscopic beneficial effects, 
treatment with pentamidine also resulted in microscopic amelioration of intestinal 
inflammation as demonstrated by the reduction of MPO activity, a marker of tissue 
neutrophils activation, and of macrophage mucosal infiltration. Very interestingly, we found 
that the treatment with pentamidine induced p53 expression on infiltrating macrophages. We 
know that S100B inhibits p53 activity and that pentamidine inhibits S100B overexpression. 
Thus, we may speculate that pentamidine, through the inhibition of S100B, induces p53 
expression indirectly driving macrophages apoptosis. This trend could also explain the anti-
inflammatory effect exerted by pentamidine. 
As expected, DSS treatment caused a marked increase in COX-2 and iNOS protein 
expression in the colon accompanied by a significant release of PGE2 and NO in the plasma. 
Such increase was significantly and dose-dependently reduced by pentamidine treatment. We 
previously demonstrated that during intestinal inflammation, S100B rises up to micromolar 
concentrations, further amplifying inflammatory responses [6,8,12]. In these conditions, 
S100B induces lipid peroxidation and activates p38 MAPK phosphorylation leading, in turn, 
to NF-κB activation and proinflammatory cytokines release. Here again, we report that 
pentamidine treatment resulted in a significant inhibition of lipid peroxidation, p38MAPK 
activation and relative stabilization of NF-κB in the cytoplasm by targeting S100B activity. 
These results further confirm that pentamidine, by interfering at the p53 binding site on 
S100B protein, drastically reduces inflammatory events induced by S100B, leading to the 
overall improvement of intestinal inflammation. 
Given the well-described inhibitory effect exerted by pentamidine on S100B activity [17], we 
evaluated whether it could negatively control enteric gliosis, thus exerting a negative 
modulation of intestinal inflammation. The administration of DSS demonstrated an enormous 
increase of both S100B and GFAP protein expression. Pentamidine was not capable of 
negatively modulating S100B protein expression in tissues and its release in plasma, while it 
was able to induce a significant decrease in GFAP protein expression. This data could be 
explained by the fact that since pentamidine inhibits the activity but not the 
expression/release of S100B [17], this drug may prevent the downstream effects due to the 
over-release of S100B during intestinal inflammation. In an autocrine manner, S100B 
induces proliferation of glial cells and, thus, increase in GFAP expression. We can thus 
speculate that pentamidine, by the inhibition of S100B activity, may control glial 
proliferation as highlighted by the decrease in GFAP expression. Alternatively, the ability of 
pentamidine to significantly reduce the expression of GFAP may be secondary to the reduced 
levels of inflammatory cytokines that have been previously demonstrated to drive glial 
proliferation [32]. 
Since S100B release has been reported to increase macrophage activity causing 
proinflammatory responses [33], we wondered whether the anti-inflammatory effect exerted 
by pentamidine on acute intestinal inflammation could be the result of the direct targeting of 
S100B in the glial network or the consequence of the indirect effect on infiltrating immune 
cells in the mucosa. We used organotypic cultures of isolated mucosa or LMMP preparations 
[24] and we challenged them with DSS plus LPS in the presence or absence of pentamidine. 
Our results demonstrated that pentamidine was able to significantly and concentration-
dependently inhibit LPS + DSS-induced NO2-, PGE2, IL-1β and TNF-α release in LMMP but 
not in mucosal preparations. This result suggests that pentamidine needs S100B to exert its 
anti-inflammatory properties. To confirm such hypothesis, we challenged mucosa 
preparations with exogenous S100B in the presence or absence of pentamidine. Interestingly, 
we found that pentamidine significantly reversed S100B-induced release of inflammatory 
mediators, thus demonstrating that anti-inflammatory properties of pentamidine are 
dependent on S100B. 
Conclusions 
Pentamidine may be putatively proposed as a new drug able to control the acute phase of 
intestinal inflammation, likely by acting on glial activation and thus inhibiting the deleterious 
cascade induced by S100B protein. Because of its well-known pharmacological and 
toxicological profile, at present, pentamidine might be regarded as a potential, innovative, 
manageable, and low-cost tool against colitis. 
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